Savak Teymoorian, MD
Ophthalmology · Laguna Hills, CANPI 1306026281
Payments from drug & device makers
Across 1,290 payments — averaging $1025.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$874K
- Glaukos Corporation$284K
- Aerie Pharmaceuticals, Inc.$135K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$9K
- Ocular Therapeutix, Inc.$6K
- Microsurgical Technology, Inc.$6K
- plus $9K from 18 others
What the payments were for
- Consulting fees$374,58639%
- Speaking & faculty fees$513,40354%
- Travel & lodging$44,7865%
- Food & beverage$22,4442%
- Education$1200%
- Gifts$620%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 767 | $874,305 |
| Glaukos Corporation | 162 | $284,284 |
| Aerie Pharmaceuticals, Inc. | 131 | $134,674 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 25 | $9,250 |
| Ocular Therapeutix, Inc. | 23 | $6,252 |
| Microsurgical Technology, Inc. | 1 | $5,500 |
| Alcon | 94 | $3,048 |
| Omeros Corporation | 4 | $2,375 |
| Kala Pharmaceuticals, Inc. | 3 | $1,255 |
| NEW World Medical,inc. | 9 | $744 |
| Tarsus Pharmaceuticals, Inc. | 14 | $360 |
| Novartis | 13 | $229 |
| Bausch & Lomb Americas Inc. | 10 | $198 |
| Thea Pharma Inc. | 9 | $189 |
| Shire North American Group Inc | 8 | $139 |
| Sun Pharmaceutical Industries Inc. | 4 | $106 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $63 |
| Amgen(2 entities) | 2 | $55 |
| Akorn, Inc. | 3 | $52 |
| Oyster Point Pharma, Inc. | 2 | $41 |
| Ivantis, Inc | 1 | $30 |
| Biotissue Holdings Inc. | 1 | $25 |
| Nova Eye, Inc. | 1 | $25 |
| Carl Zeiss Meditec, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DURYSTA$378,785
- Rocklatan$111,953
- iDose$101,230
- Rhopressa$97,078
- LUMIGAN$58,046
- VUITY$38,004
- COMBIGAN$34,868
- Travoprost Intraocular Implant - iDose$28,682
- iStent inject Trabecular Micro-Bypass Stent System$23,209
- iDose TR$18,706
- RESTASIS$16,425
- iStent Trabecular Micro-Bypass Stent System$15,817
- ALPHAGAN P$12,700
- XEN$6,184
- DEXTENZA$5,887
- VYZULTA$5,123
- PROLENSA$3,660
- OMIDRIA$2,375
- iStent inject W$2,250
- iAccess Precision Blade$2,250
How this compares
$1,323,216 in reported general payments places this provider in the 95th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 451 | $269,038 |
| RestasisCyclosporine | 58 | $74,944 |
| CombiganBrimonidine Tartrate/Timolol | 97 | $52,664 |
| RhopressaNetarsudil Mesylate | 81 | $40,345 |
| Alphagan PBrimonidine Tartrate | 73 | $37,009 |
| ProlensaBromfenac Sodium | 108 | $35,683 |
| VyzultaLatanoprostene Bunod | 60 | $33,652 |
| ZioptanTafluprost/Pf | 40 | $21,537 |
| RocklatanNetarsudil Mesylat/Latanoprost | 39 | $21,174 |
| AzoptBrinzolamide | 15 | $9,414 |
| Timolol Maleate | 337 | $9,290 |
| Latanoprost | 674 | $9,171 |
| Bromfenac Sodium | 47 | $8,947 |
| Prednisolone Acetate | 204 | $6,661 |
| InveltysLoteprednol Etabonate | 21 | $6,175 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $874,305 | $433,655679 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $134,674 | $61,519120 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $9,250 | $35,683108 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $198 | $33,65260 claims |
| Akorn, Inc.Zioptan, Betimol | $52 | $24,98851 claims |
| AlconAzopt, Simbrinza | $3,048 | $15,31340 claims |
| Kala Pharmaceuticals, Inc.Inveltys | $1,255 | $6,17521 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Laguna Hills
- John HovanesianLaguna Hills$3.7M
- Nisha AcharyaSan Francisco$33M
- David WirtaNewport Beach$18.4M
- Michael IpPasadena$10.2M
- Raymond DouglasBeverly Hills$9.7M
- Sherif El HaraziGlendale$9.2M
- Daniel SchwartzSan Francisco$8M
- Nikolas Londonla Jolla$6.1M
- Michael BerlinWest Hollywood$5.7M
- Steven JacobsonLos Angeles$4.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.